Trial Profile

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Checkpoint Inhibitor Naïve Subjects With Advanced Or Metastatic Merkel Cell Carcinoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IFx 2.0 (Primary) ; Pembrolizumab (Primary)
Indications Merkel cell carcinoma
Focus Adverse reactions
Sponsors TuHURA Biosciences

Most Recent Events

15 Oct 2025 Planned initiation date (estimated date of first patient enrollment) changed from 30 Apr 2025 to 1 Oct 2025.
05 May 2025 According to a TuHURA Biosciences media release, the company announced that data from the trial is anticipated by the end of Q4 2025 or early Q1 2026.
05 May 2025 Status changed to recruiting according to a TuHURA Biosciences media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com